Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
This study provides compelling evidence on the role of adjuvant chemotherapy in hormone-receptor–positive, HER2-negative breast cancer with positive lymph nodes, revealing a significant impact based on menopausal status.
Oncology, Medical October 2nd 2023
Cancer Therapy Advisor
Recent findings from the MARS 2 trial challenge traditional treatment protocols for mesothelioma, indicating that chemotherapy alone may offer improved outcomes over combined surgical approaches. Discover why experts are re-evaluating long-standing surgical treatments.
Oncology, Medical September 25th 2023
Dana-Farber Cancer Institute
Discover how the FLAURA2 trial’s findings on combination therapy could revolutionize initial treatment plans for NSCLC patients with EGFR mutations. Learn more about the significant extension in progression-free survival and its potential clinical implications.
DocWire News
The targeted chemotherapy pill AOH1996, developed by the City of Hope, has shown promising results in preclinical research by targeting PCNA, a protein once thought to be too challenging for targeted therapy. Explore the potential of this novel approach as it advances to phase 1 clinical trials.
Oncology, Medical August 14th 2023
This phase 2 trial demonstrates the potential of perioperative nivolumab combined with chemotherapy in achieving higher pathological complete response and survival rates in stage III NSCLC. Explore the detailed findings to understand how this approach may influence future treatment paradigms.
Cancer Care Business Exchange (CBEx)
The chemotherapy shortage in the US is a pressing issue that demands a reevaluation of health policies. Dive deeper into the potential strategies for mitigating its impact, from creating a market for high-quality generics to convening a multi-stakeholder task force.
Oncology, Medical August 7th 2023